Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin
Lung cancer remains the leading cause of cancer associated deaths worldwide. Recent efforts have been focused on combinational and nanoparticulate therapies that can efficiently deliver multiple therapeutics. Herein, we reported cetuximab (CET) functionalized, paclitaxel (PTX) and 5-Demethylnobileti...
Main Authors: | Shenghu Guo, Yuehua Zhang, Zheng Wu, Lei Zhang, Dongwei He, Xing Li, Zhiyu Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332219322504 |
Similar Items
-
The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane
by: Ki-Hyun Bang, et al.
Published: (2019-06-01) -
Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells
by: Jianwen Zhou, et al.
Published: (2019-01-01) -
Anti-inflammatory effects of 4′-demethylnobiletin, a major metabolite of nobiletin
by: Xian Wu, et al.
Published: (2015-12-01) -
Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01) -
Improving the bioaccessibility and in vitro absorption of 5-demethylnobiletin from chenpi by se-enriched peanut protein nanoparticles-stabilized pickering emulsion
by: Fangjian Ning, et al.
Published: (2019-04-01)